EUVIMEDEUVIMED entdecken
Open Access

Baseline Tumor Biology Predicts Survival After Recurrence in Gastric Cancer: Impact of LVI, PNI, and HER2 Status

Gözde Ağdaş iD, Mehmet Salim Demir iD

Medical Science Monitor · 2026

DOI: 10.12659/msm.951829 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical Science Monitor, 2026. Verfasst von Gözde Ağdaş und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Van Training and Research Hospital, Van, Turkey. Hauptthemen laut MEDLINE: Stomach Neoplasms, Erb-b2 Receptor Tyrosine Kinases. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsErb-b2 Receptor Tyrosine KinasesHumansFemaleNeoplasm Recurrence, LocalRetrospective StudiesMaleMiddle AgedPrognosisDisease-Free SurvivalAgedNeoplasm InvasivenessGastrectomyKaplan-Meier EstimateAdultLymphatic MetastasisBiomarkers, Tumor

Substanzen

Erb-b2 Receptor Tyrosine KinasesERBB2 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Medical Oncology, Van Training and Research Hospital, Van, Turkey.

ORCID-Profile: Gözde Ağdaş, Mehmet Salim Demir

Zitieren

APA

Ağdaş, G., & Demir, M. S. (2026). Baseline Tumor Biology Predicts Survival After Recurrence in Gastric Cancer: Impact of LVI, PNI, and HER2 Status. Medical Science Monitor. https://doi.org/10.12659/msm.951829

Vancouver

Ağdaş G, Demir MS. Baseline Tumor Biology Predicts Survival After Recurrence in Gastric Cancer: Impact of LVI, PNI, and HER2 Status. Medical Science Monitor. 2026. doi:10.12659/msm.951829

BibTeX
@article{Ada2026,
  author = {Ağdaş, Gözde and Demir, Mehmet Salim},
  title = {Baseline Tumor Biology Predicts Survival After Recurrence in Gastric Cancer: Impact of LVI, PNI, and HER2 Status},
  journal = {Medical Science Monitor},
  year = {2026},
  doi = {10.12659/msm.951829}
}
Kostenlos starten →